Although ␥-aminobutyric acid type A receptor agonists and antagonists bind to a common site, they produce different conformational changes within the site because agonists cause channel opening and antagonists do not. We used the substituted cysteine accessibility method and two-electrode voltage clamping to identify residues within the binding pocket that are important for mediating these different actions. Each residue from ␣ 1 T60 to ␣ 1 K70 was mutated to cysteine and expressed with wild-type ␤ 2 subunits in Xenopus oocytes. Methanethiosulfonate reagents reacted with ␣ 1 T60C, ␣ 1 D62C, ␣ 1 F64C, ␣ 1 R66C, ␣ 1 S68C, and ␣ 1 K70C. ␥-Aminobutyric acid (GABA) slowed methanethiosulfonate modification of ␣ 1 F64C, ␣ 1 R66C, and ␣ 1 S68C, whereas SR-95531 slowed modification of ␣ 1 D62C, ␣ 1 F64C, and ␣ 1 R66C, demonstrating that different residues are important for mediating GABA and SR-95531 actions. In addition, methanethiosulfonate reaction rates were fastest for ␣ 1 F64C and ␣ 1 R66C, indicating that these residues are located in an open, aqueous environment lining the core of the binding pocket. Positively charged methanethiosulfonate reagents derivatized ␣ 1 F64C and ␣ 1 R66C significantly faster than a negatively charged reagent, suggesting that a negative subsite important for interacting with the ammonium group of GABA exists within the binding pocket. Pentobarbital activation of the receptor increased the rate of methanethiosulfonate modification of ␣ 1 D62C and ␣ 1 S68C, demonstrating that parts of the binding site undergo structural rearrangements during channel gating.
have addressed the question of how the binding of compounds with divergent structure leads to dramatic functional differences.
For example, agonist binding induces conformational changes that result in channel opening, whereas binding of competitive antagonists does not. Distinguishing the specific amino acid residues involved in the binding of agonists and antagonists will help to elucidate the structural rearrangements that govern the pharmacological effects of these compounds. In this paper, we examined the molecular determinants important for the binding of the agonist GABA and the competitive antagonist SR-95531 to the ␥-aminobutyric acid type A (GABA A ), receptor and explored the conformational changes that occur within the GABA-binding site during channel activation by a barbiturate.
GABA A receptors are heteropentameric chloride channels that mediate fast synaptic inhibition in the brain and are members of an evolutionarily related superfamily of LGICs that also includes nicotinic acetylcholine, glycine, and serotonin-type 3 receptors (1). To date, 16 different GABA A receptor subunit isoforms (␣ [1] [2] [3] [4] [5] [6] , ␤ 1-3 , ␥ 1-3 , ␦, ⑀, , and ) have been cloned (2) (3) (4) (5) (6) (7) . Most native receptors are thought to contain ␣, ␤, and ␥ subunits (8) in a 2:2:1 stoichiometry (9), although functional channels that lack benzodiazepine modulation can be formed without the ␥ subunit (10, 11) .
The neurotransmitter recognition site, where agonists such as GABA and muscimol and antagonists such as SR-95531 and bicuculline bind, is located at the interface between the ␣ and ␤ subunits because residues have been identified on both subunits that are important for ligand recognition. On the ␣ 1 subunit, residues identified include Phe 64 (12, 13) , Arg 66 , Ser 68 (14) , Arg 119 , and Ile 120 (15, 16 (17, 18) have been identified. Based on work on the related nicotinic acetylcholine receptor, residues that contribute to forming the binding site are located in at least six different non-contiguous extracellular N-terminal regions of the ␣ and ␤ subunits. These regions have been designated loops A-F (19) . Residues within these loops likely have different functional roles. Some residues may directly contact ligand, some may be important for maintaining the structural integrity of the binding site, and others may mediate local conformational movements within the site.
In the present study, we examined the binding site region surrounding ␣ 1 F64 (loop D) of the GABA A receptor. In the homologous region of the serotonin-type 3 receptor, White and colleagues (20) used alanine-scanning mutagenesis and determined that different amino acid residues contribute to the binding of agonists and antagonists. We hypothesized that the region surrounding ␣ 1 F64 of the GABA-binding site also contains unique residues important for agonist and antagonist binding, and we tested this hypothesis by using the substituted cysteine accessibility method (SCAM).
SCAM has been used on a variety of ion channels to elucidate channel lining and binding site residues, to determine the location of channel gates and selectivity filters, and to identify regions of the protein that are involved in conformational rearrangements during state changes (21) . In this method, individual amino acid residues are mutated to cysteine, and the ability of sulfhydryl-specific reagents to modify covalently each introduced cysteine is assessed by observing the effect of the reagent on receptor function. We measured the rates of sulfhydryl modification of accessible introduced cysteine residues in the presence and absence of GABA and SR-95531. We identified a subsite important for agonist binding that includes ␣ 1 F64, ␣ 1 R66, and ␣ 1 S68 and an antagonist-binding subsite that includes ␣ 1 D62, ␣ 1 F64, and ␣ 1 R66. In addition, we used sulfhydryl-specific reagents of different charge and determined that a negative subsite exists within the binding pocket. Finally, we measured rates of sulfhydryl modification in the presence of pentobarbital (a GABA A receptor modulator that opens the channel), and we identified conformational changes that occur within the GABA-binding site during channel activation.
EXPERIMENTAL PROCEDURES
Site-directed Mutagenesis-The ␣ 1 cysteine mutants were engineered using the Altered Sites II® in vitro Mutagenesis Systems (Promega Corp., Madison, WI) or by recombinant PCR as described previously (14, 22 (23, 24) for expression in Xenopus laevis oocytes. The presence of the mutations was verified by restriction endonuclease digestion and double-strand cDNA sequencing. The mutants have been named, using the single letter amino acid code, as wild-type residue, residue number, and mutated residue.
Expression in Oocytes-X. laevis oocytes were prepared as described previously (25) . cRNA transcripts were generated using the mMessage T 7 kit (Ambion, Austin, TX). GABA A receptor rat ␣ 1 or ␣ 1 mutants were expressed with wild-type rat ␤ 2 subunits by injection of cRNA into oocytes (0.3 ng of cRNA/subunit/oocyte, except for ␣ 1 F64C␤ 2 and ␣ 1 R66C␤ 2 that were injected at 7 ng of cRNA/subunit to ensure high levels of receptor expression). Mean maximal responses to GABA ranged from 1 to 10 A. The oocytes were stored in ND96 medium (in mM: 96 NaCl, 2 KCl, 1 MgCl 2 , 1.8 CaCl 2 , and 5 HEPES, pH 7.4) supplemented with 100 g/ml gentamicin and 100 g/ml bovine serum albumin for 2-14 days and used for electrophysiological recordings.
FIG. 1.
Effects of MTS reagents on wild-type and mutant GABA A receptors. A, structures and lengths of MTS reagents. Shown are the portions of the MTS reagents that covalently modify an introduced cysteine. Lengths were measured after energy minimization (Ͻ0.5 kcal/Å; Chemsketch, ADC, Toronto, Ontario, Canada). B, amino acid residues ␣ 1 T60-␣ 1 K70 were individually mutated to cysteine and expressed with ␤ 2 subunits in Xenopus oocytes. By using two-electrode voltage clamping, the accessibility of the introduced cysteines to MT-SEA, MTSET, and MTSES was examined. The absolute change in GABA-mediated current after MTS treatment is plotted for wild-type (WT) and mutant receptors (percent effect ϭ ( 1 Ϫ(I GABA, after /I GABA, before)) ϫ 100 ). ‡, percent effect reflects inhibition of current for all mutants except T60C where currents were increased after application of MTS reagents. *, cysteine substitution was not tolerated at these positions.
FIG. 2. Measurement of MTS reaction rates.
A, representative current trace recorded while measuring the reaction rate of MTSES at ␣ 1 R66C␤ 2 receptors. Downward deflections represent inward currents elicited by 6-s applications of 1 mM GABA (ϳEC 25 ). Bars indicate the time of application of GABA or MTSES. MTSES (500 M) was applied for 20 s each time. B, the logarithms of the ratio of the second-order rate constants (k 2 ) of the positively charged MTSET over the negatively charged MTSES for 2-ME, ␣ 1 F64C, ␣ 1 R66C, and ␣ 1 S68C are shown. All data represent the mean Ϯ S.E. of at least 4 experiments. The k 2 values are listed in Table I . Cationic MTSET reacts significantly faster than anionic MTSES at ␣ 1 F64C and ␣ 1 R66C. The rates for 2-ME were reported by Karlin and Akabas (21) .
Voltage Clamp Analysis-Oocytes under two-electrode voltage clamp (V hold of Ϫ80 mV) were continuously perfused with ND96 at a rate of 5 ml/min. The bath volume was 200 l. GABA, SR-95531 (Sigma), pentobarbital (Research Biochemicals, Natick, MA), and methanethiosulfonate (MTS) reagents (Toronto Research Chemicals, Toronto, Ontario, Canada) were dissolved in ND96. Standard two-electrode voltage clamp recording was carried out using a GeneClamp 500 amplifier (Axon Instruments, Foster City, CA) interfaced to a computer with a Digidata 1200 (Axon Instruments). Electrodes were filled with 3 M KCl and had resistances of 0.5-2.0 megaohms in ND96. Data acquisition and analysis were performed using pClamp 6 (Axon Instruments).
Pulse Protocol for Measuring MTS Effects-The sulfhydryl-specific reagents used were derivatives of MTS obtained from Toronto Research Chemicals (Toronto, Ontario, Canada). The reagents used were 2-aminoethyl methanethiosulfonate (MTSEA), 2-(trimethylammonium)ethyl methanethiosulfonate (MTSET), and 2-sulfonatoethyl methanethiosulfonate (MTSES). All oocytes were stabilized before addition of MTS reagent by application of GABA (5 s) at 10-min intervals until the GABA-activated peak currents (I GABA ) varied by Ͻ10%. GABA concentrations used were EC 40 -EC 60 for each mutant. After the GABA response stabilized, freshly diluted MTS reagent was applied for 2 min; the cell was washed for 5 min, and then GABA was applied at the same concentration used before the MTS treatment. MTSEA (2 mM), MTSET (2 mM), or MTSES (5 mM) were used. The effect of the MTS reagent was calculated as (I GABA-post /I GABA-pre ) Ϫ 1, where I GABA-post is the current elicited by GABA after MTS application, and I GABA-pre is the current elicited by GABA before MTS application.
Rate of MTS Modification-The rate of MTS reagent covalent modification of introduced cysteines was determined by measuring the outcome of sequential applications of MTS reagents on I GABA . The protocol was as follows: EC 20 -EC 60 GABA was applied for 5 s; the cell was washed for 30 s; MTS reagent was applied for 5-20 s; the cell was washed for 2.5 min; and the procedure was repeated until I GABA no longer changed indicating that the reaction was complete. Before the rate of MTS modification was measured, GABA was applied every 3 min until I GABA stabilized to within 3% demonstrating that the observed changes in I GABA after application of MTS reagent were due to the effects of the MTS reagent. , in which case they were co-applied with MTSEA. For these studies, I GABA was stabilized before the rate of MTS reaction was measured as follows: apply GABA (EC 20 -60 ) for 5 s, wash for 30 s, apply GABA, SR-95531, or pentobarbital at high concentration for 5-20 s, wash for 2.5 min, and repeat the procedure. This procedure was repeated until the peak of the GABA (EC 20 -60 ) current was within 3% of the previous GABA (EC 20 -60 ) current peak.
For all rate experiments, the decrease in current was plotted versus cumulative time of MTS exposure. We assume that the concentration of MTS reagent does not change significantly during the reaction, and thus, we can determine a pseudo first-order rate constant from the rate of decrease in I GABA . Peak current at each time point was normalized to the initial peak current, and a pseudo first-order rate constant (k 1 ) was determined by fitting the data with a single exponential decay equation: y ϭ span⅐e Ϫkt ϩ plateau. Because the data are normalized to I GABA at time 0, span ϭ 1 Ϫ plateau. The second-order rate constant (k 2 ) for MTS reaction was determined by dividing the calculated pseudo first-order rate constant by the concentration of MTS reagent used (26) . To verify the accuracy of this protocol, second-order rate constants were determined using at least two different concentrations of MTS reagents for several mutants.
EC 50 Analysis-Concentration-response experiments were performed as described previously (14) . In brief, these trials used a low concentration of GABA (EC 2 -EC 7 ) immediately before the test concentration of agonist to correct for any slow drift in GABA responses that may occur during the experiment. Currents elicited by each test concentration were normalized to the corresponding low concentration current before curve fitting. Concentration-response data were fit to the following equation:
n ), where I is the peak response to a given concentration of GABA; I max is the maximum amplitude of current; EC 50 is the concentration of GABA that produces a half-maximal response; [A] is the concentration of GABA; and n is the Hill coefficient.
IC 50 Analysis-IC 50 values were measured as described previously (18) . SR-95531 IC 50 values were measured by applying a fixed concentration of GABA (EC 20 -EC 60 ) immediately followed by co-application of the same concentration of GABA and a test concentration of SR-95531. Inhibition was calculated as I GABA ϩ SR-95531 /I GABA . Data were fit to the following equation:
n ), where IC 50 is the concentration of antagonist that blocks half of I GABA ; [Ant] is the concentration of antagonist, and n is the Hill coefficient. K I values were calculated using the Cheng-Prusoff/Chou equation (27, 28) :
is the concentration of GABA used, and EC 50 is the concentration of GABA that elicits a half-maximal response.
Statistical Analysis-Data analysis was carried out using nonlinear regression analysis included in the GraphPad Prism software package (San Diego, CA; www.graphpad.com). Statistical analysis was conducted using a one-way analysis of variance, followed by a post hoc Dunnett's test.
Measurement of Length of MTS Reagents, GABA, and SR-95531-All compounds were measured after energy minimization (Ͻ0.5 kcal/Å; Chemsketch, ADC, Toronto, Ontario, Canada). All MTS regents were measured from the sulfur to the center of the base of the tetrahedron formed by the terminal tertiary group. GABA was measured from the nitrogen to the base of the tetrahedron formed by the carboxyl group. SR-95531 was measured from the carbon of the methyl group to the center of the base of tetrahedron formed by the carboxyl group.
Structural Modeling-The mature protein sequences of the rat ␣ 1 and ␤ 2 subunits were homology modeled with a subunit of the acetylcholine-binding protein (AChBP) (29) . The crystal structure of the AChBP was downloaded from the RCSB Protein Data Bank (code 1I9B) Table II . GABA concentration-response curves are from data reported in Boileau et al. (14) . and loaded into Swiss Protein Data bank Viewer (SPDBV, ca.expasy-.org/spdbv). The ␣ 1 protein sequence from Thr 12 -Ile 227 and the ␤ 2 protein sequence from Ser 10 -Leu 218 were aligned with the AChBP sequence using the alignment function of SPDBV. The aligned sequences of the ␣ 1 and ␤ 2 subunits were threaded onto an AChBP subunit using the "Interactive Magic Fit" function of SPDBV. The threaded subunits were imported into SYBYL (Tripos, Inc., St. Louis, MO) where energy minimization was carried out with the first 100 iterations carried out using Simplex minimization followed by 10,000 iterations using the Powell method.
RESULTS

Modification of Cysteine Mutants by MTS Reagents-
We reported previously that when mutated to cysteine, alternating residues from ␣ 1 T60 to ␣ 1 S68 are accessible to covalent modification by MTSEA-biotin, suggesting that this region of the GABA-binding site forms a ␤-strand (14) . We also determined that the presence of GABA inhibits the reaction of MTS compounds at ␣ 1 F64C, ␣ 1 R66C, and ␣ 1 S68C, indicating that these residues may face into the agonist-binding pocket. In the present study, we used MTS reagents of different size and charge to explore the physicochemical environment of this region of the GABA-binding site. The MTS reagents used were MTSEA (3.7 Å long), which covalently adds a positively charged ethyl-ammonium group, MTSET (4.5 Å), which adds a positively charged ethyl-trimethylammonium group, and MTSES (4.8 Å), which adds a negatively charged ethyl-sulfonate group (Fig. 1) .
In order to determine the ability of the MTS reagents to react with each introduced cysteine, mutant ␣ 1 and wild-type ␤ 2 subunits were co-expressed in Xenopus oocytes, and I GABA (EC 40 -60 ) was measured before and after a 2-min MTS application. Because the MTS reagents did not affect the amplitude of I GABA at wild-type ␣ 1 ␤ 2 receptors, we assumed that current changes observed in mutant receptors were due to covalent modification of the introduced cysteine residues (Fig. 1) . In general, the residues that were reported previously (14) to be modified by MTSEA-biotin (␣ 1 T60C, ␣ 1 D62C, ␣ 1 F64C, ␣ 1 R66C, and ␣ 1 S68C) were also accessible to modification by MTSEA, MTSET, and MTSES (Fig. 1) . Reaction with MTS reagents reduced GABA current by 14 (␣ 1 K70C, MTSET) to 96% (␣ 1 F64C, MTSEA). In contrast to all other mutants, covalent modification of ␣ 1 T60C caused an increase in I GABA suggesting that the GABA EC 50 value for this mutant receptor decreases following covalent modification.
At any given position, the magnitude of the MTS effect on I GABA was dependent on the specific MTS reagent used (Fig. 1) . The observed differences in MTS effects may be due to the charge and/or size of the functional group tethered within the binding site. However, it is also possible that the MTS reactions did not go to completion due to their varied intrinsic reactivities (21) . To test this possibility, we measured the rate at which each MTS reagent modified ␣ 1 D62C, ␣ 1 F64C, ␣ 1 R66C, and ␣ 1 S68C, making sure that each reaction was followed to completion.
MTS Reaction Rate Constants-The rates of covalent modification of an introduced cysteine were obtained by measuring the effect of successive subsaturating applications of each MTS reagent on I GABA (Fig. 2A) . The decrease in I GABA was plotted versus cumulative duration of MTS exposure and fit with a one-phase exponential decay curve, which yields a pseudo firstorder rate constant (k 1 ). To correct for the concentration dependence of the rate, a second-order rate constant (k 2 , Table I ) was calculated by dividing k 1 by the concentration of MTS used ("Experimental Procedures"). In general, the maximal effects of the MTS reagents observed in the rate experiments were consistent with those measured in the 2-min pulse protocol (mutant: MTSEA maximal inhibition/MTSEA 2-min inhibition; ␣ 1 D62C: 64/54%; ␣ 1 F64C: 92/96%; ␣ 1 R66C: 32/33%; ␣ 1 S68C: 34/32%). Because the reactions went to completion, these data indicate that tethering groups of different size and charge to the mutant receptors differentially affects I GABA .
The rate of reaction of MTS modification of a binding site engineered cysteine depends on several factors as follows: 1) the movement of the MTS reagent from bulk solution to the substituted cysteine in the binding pocket (permeability of the pathway); 2) the intrinsic electrostatic potential within the 
a NR is no reaction. pocket and along the pathway; 3) the ionization (acid dissociation) of the substituted cysteine's sulfhydryl group; and 4) steric restrictions in forming an activated complex between the thiolate of the substituted cysteine and the MTS reagent. MTS reagents react preferentially with the ionized thiolate (RSϪ) form of cysteine (30, 31) . Of the residues tested, covalent modification of ␣ 1 F64C was the fastest, indicating that this is the most accessible residue in loop D. For example, MTSET modified ␣ 1 F64C with a k 2 of ϳ5,500,000 M Ϫ1 s Ϫ1 , which was about 340-fold faster than reaction at ␣ 1 R66C. Reaction at ␣ 1 R66C, in turn, was about 40-fold faster than modification at ␣ 1 S68C (Table I) . At ␣ 1 D62C, MTSEA was the only reagent tested that significantly altered I GABA . There are two possible explanations for this result. Either MTSET and MTSES do not react with ␣ 1 D62C or covalent modification by these reagents does not change I GABA , implying that any apparent modification is functionally silent. To test these possibilities, we measured the ability of MTSEA to modify covalently ␣ 1 D62C after application of MTSET or MTSES. If MTSET or MTSES modified ␣ 1 D62C, then reaction with MTSEA should not occur, and no change in I GABA should be observed. Application of MTSES or MTSET prior to MTSEA had no effect on the ability of MTSEA to inhibit I GABA (data not shown), indicating MTSET and MT-SES do not react with ␣ 1 D62C. It should be noted that the reaction rate of MTSEA with ␣ 1 D62C was very slow (k 2 ϭ 16 M Ϫ1 s Ϫ1 ) indicating that ␣ 1 D62C has limited accessibility. In free solution, the rates of MTSEA, MTSET, and MTSES with 2-mercaptoethanol (2-ME) are 76,000, 212,000, and 17,000 M Ϫ1 s Ϫ1 , respectively (21) ( Table I ). The rate constants depend on the charges of the reactants. Because the net charge of 2-ME is Ϫ1, positively charged MTS reagents react faster than negatively charged MTS reagents with this compound (31) . Interestingly, the reaction rate constants of MTSET and MTSEA with ␣ 1 F64C were ϳ30-fold faster than the their rates of reaction with 2-ME in free solution (Table I ). The rate of reaction of the MTS reagents with ␣ 1 F64C is influenced by the intrinsic electrostatic potential of the GABA-binding site, which arises from fixed charges and dipoles in the protein. The faster rates of MTSET and MTSEA modification of ␣ 1 F64C compared with the rates of modification of a simple thiol in solution are likely due to these intrinsic properties of the protein and suggest that the short range interactions of MTSET and MTSEA with the GABA-binding site are stronger than those with a simple thiol. Similar fast rates were measured for MTSET and MTSEA reaction with the acetylcholine-binding site cysteines, ␣C192/193, in reduced, wild-type Torpedo nicotinic acetylcholine receptors, k 2 ϳ3 ϫ 10 6 M Ϫ1 s Ϫ1 (31) . Intrinsic Negative Electrostatic Potential in the GABA-binding Site-The intrinsic electrostatic potential at a substituted cysteine can be examined by determining the rate of reactions of MTS reagents that differ in charge (26, 31, 32) . We examined the electrostatic potential at ␣ 1 F64C, ␣ 1 R66C, and ␣ 1 S68C by comparing the rates of reaction of the positively charged MT-SET and the negatively charged MTSES (Fig. 2B) . Because MTSET and MTSES are approximately equivalent in size and have a common reaction mechanism, differences in their respective rates of reaction at a given residue are likely due to their opposite charges. The second-order rate constants for MTSET modification of ␣ 1 F64C, ␣ 1 R66C, and ␣ 1 S68C were 235-, 2320-, and 10.4-fold faster than that for MTSES, respectively (Table I and Fig. 2B ). In comparison, the second-order rate constant for MTSET modification of 2-ME is 12.5-fold faster than that for MTSES. To factor out the intrinsic differences in the reactivities of the two MTS reagents and the extent of ionization of the respective thiols, we divided the ratio of the rates of the two reagents at an introduced cysteine by the ratio of the rates for the two reagents with 2-ME (31-33). For ␣ 1 F64C, the ratio of ratios is ϭ 235/12.5 ϭ 18.8. For ␣ 1 R66C and ␣ 1 S68C, ϭ 185.6 and 0.84, respectively. A ratio of ratios that is significantly larger than one indicates that there is a negative potential experienced by that thiol. A ratio of ratios of ϳ1 indicates that there is no charge selectivity for the reaction with this residue. We can estimate the effective electrostatic potential at an introduced cysteine as shown in Equation 1,
where z is the charge of the MTS reagent; R is the gas constant; T is absolute temperature, and F is Faraday's constant (31, 32) . The calculated electrostatic potential at ␣ 1 F64C is Ϫ37 mV and the potential at ␣ 1 R66C is Ϫ66 mV. The negative potential may be smaller at ␣ 1 F64C because of the nearby positively charged arginine at position 66. The data indicate that there is a substantial negative potential experienced by ␣ 1 F64C and ␣ 1 R66C and that a negative subsite exists within the GABA-binding pocket that interacts with the positive charge on MTSET and MTSEA during their reaction with ␣ 1 F64C or ␣ 1 R66C. Expression and Functional Analysis of ␣ 1 R66 MutationsBecause GABA is zwitterionic, it is plausible that both a positively and a negatively charged subsite are involved in its binding. One residue within loop D that could be part of a positive subsite is ␣ 1 R66. Previously, we determined that cysteine substitution at ␣ 1 R66 increased the GABA EC 50 value 320-fold (14) . We mutated ␣ 1 R66 to other residues including alanine, histidine, leucine, serine, glutamine, and the positively charged lysine. In each case, the GABA EC 50 values were increased by more than 2 orders of magnitude compared with wild-type receptors (R66A, 1000 Ϯ 510 M; R66H, 6200 Ϯ 1500 M; R66L, 1400 Ϯ 400 M; R66S, 2700 Ϯ 375 M; R66Q, 5300 Ϯ 1700 M; R66K, 5600 Ϯ 350 M; WT, 8.2 Ϯ 0.4 M). We calculate that the change in free energy due to ␣ 1 R66 mutation is ϳ3-4 kcal/mol. These data suggest that the positively charged arginine at position 66 may play a critical role in agonist binding.
We also measured the K I values for the antagonist SR-95531 in oocytes expressing ␣ 1 D62C, ␣ 1 F64C, ␣ 1 R66C, or ␣ 1 S68C. 
a Rates of reaction in the presence of ligand that were statistically different from control (p Ͻ 0.001).
Whereas mutations at ␣ 1 F64 and ␣ 1 R66 altered GABA EC 50 values, SR-95531 K I values were only altered by cysteine substitution at ␣ 1 F64 (180-fold, Table II and Fig. 3 ). Because SR-95531 is a larger molecule than GABA, it is likely to be stabilized by different amino acid residues within the binding pocket. These data indicate that within the GABA-binding site there are distinct residues important for agonist and antagonist binding. In this paper, the term "GABA subsite" refers to residues within the overall binding pocket that are important for GABA binding. Similarly, the term "SR-95531 subsite" refers to residues within the pocket that contribute to SR-95531 binding. There may be residues within the binding pocket that are involved in both GABA and SR-95531 binding, and thus the subsites may overlap.
Effects of GABA, SR-95531, and Pentobarbital on MTS Reaction Rate
Constants-To identify potential agonist and antagonist subsites, we measured the rates of MTS covalent modification of ␣ 1 D62C, ␣ 1 F64C, ␣ 1 R66C, and ␣ 1 S68C in the presence and absence of GABA or SR-95531 (Table III and Fig.  4) . We reasoned that if these residues line the binding pocket, then the presence of SR-95531 or GABA should slow the rate of MTS reaction due to steric hindrance. Both GABA and SR-95531 significantly slowed the rate of covalent modification at ␣ 1 F64C and ␣ 1 R66C, suggesting that these residues line a common agonist/antagonist-binding region. However, the rate of covalent modification of ␣ 1 D62C was only slowed by SR-95531, whereas the rate of modification of ␣ 1 S68C was only slowed by GABA. These results suggest that ␣ 1 D62C may form part of an antagonist subsite, whereas ␣ 1 S68C appears to form part of an agonist subsite.
GABA not only binds to the receptor but also gates the channel. Therefore, the slowing of the rate of reaction at ␣ 1 S68C in the presence of GABA could be due to conformational changes that occur when the channel opens and desensitizes rather than to a direct physical block of position ␣ 1 S68C by GABA. To distinguish between these possibilities, we measured the rate of covalent modification of ␣ 1 S68C in the presence of pentobarbital, which directly activates the channel (34, 35) by binding to a site distinct from GABA (17) .
The rates of covalent modification of ␣ 1 F64C and ␣ 1 R66C were not altered in the presence of a directly activating concentration of pentobarbital (500 M), suggesting that the opening of the channel does not change the ability of the MTS reagents to modify these residues. However, the rates of covalent modification of ␣ 1 D62C and ␣ 1 S68C were significantly accelerated in the presence of a high concentration of pentobarbital (500 M) (Fig. 5 and Table III ). Because opening of the channel with pentobarbital accelerated covalent modification and GABA slowed covalent modification of ␣ 1 S68C, we predict that GABA sterically blocks access to this residue.
Covalent modification of ␣ 1 D62C by MTSEA was slowed in the presence of SR-95531 and accelerated in the presence of pentobarbital. Although the data are consistent with SR-95531 causing a steric block and ␣ 1 D62C lining part of an antagonist subsite, it is feasible that SR-95531 could induce a conformational change in the receptor that leads to a slowing of MTSEA reaction at ␣ 1 D62C. DISCUSSION Recently, the crystal structure of the AChBP was solved (29) . The AChBP is a homologue of the extracellular N-terminal domain of the nicotinic acetylcholine receptor and binds several ligands of this receptor. The nicotinic acetylcholine receptor and the GABA A receptor are related proteins and are members of a LGIC superfamily of receptors. Thus, by using the AChBP structure as a template, we can begin to model the GABAbinding site (Fig. 6) . Our secondary structure prediction of loop D (Fig. 1) (14) agrees with the crystal structure of the AChBP (29) , where residues aligned with this region of the GABA A receptor form a ␤-strand (Fig. 6) .
In this study, we used SCAM to examine the physicochemical 40 -60 ) current traces were recorded while applying MTSES (10 M) in the presence (bottom) and absence (top) of the antagonist SR-95531 (10 M, EC 95 ). C, decreases in I GABA were plotted versus cumulative MTS exposure at ␣ 1 D62C, ␣ 1 F64C, ␣ 1 R66C, and ␣ 1 S68C containing receptors. Data obtained from individual experiments were normalized to the GABA current measured at t ϭ 0 and are presented as mean Ϯ S.D. from at least three independent experiments. Single exponential curve fits of the data reveal the effects of GABA and SR-95531 on the MTS reaction rates (q, MTS alone; OE, MTS ϩ GABA; f, MTS ϩ SR-95531). k 2 values are shown in Table III . For ␣ 1 D62C receptors MTSEA was used for covalent modification, whereas for ␣ 1 F64C, ␣ 1 R66C, and ␣ 1 S68C MTSES was used, as described under "Experimental Procedures." environment of cysteine mutants in loop D. A residue in a relatively open, aqueous environment will have a faster rate of reaction than a residue in a relatively restrictive, nonpolar environment (26) . In loop D, the fastest MTS reaction rate occurs at ␣ 1 F64C, followed by ␣ 1 R66C, ␣ 1 S68C, and ␣ 1 D62C (Table I ). In addition, MTS reagents produce the largest inhibition of I GABA at ␣ 1 F64C, followed by ␣ 1 R66C, ␣ 1 S68C, and ␣ 1 D62C (Fig. 1) . Our data indicate that ␣ 1 F64C and ␣ 1 R66C are located in an aqueous and sterically unrestricted environment. Such an environment is thought to exist within the core of the binding pocket, and we predict that these residues lie within that core. Our prediction agrees with the AChBP structure where aligned residues are located in the center of the acetylcholine-binding pocket (Fig. 6 ). In contrast, we predict that ␣ 1 D62C is located in a sterically confined region and/or its sulfhydryl chain is in a relatively hydrophobic environment that is poorly ionized, because its rate of covalent modification by MTSEA (k 2 ϭ 16 M Ϫ1 s Ϫ1 ) is ϳ150,000-fold slower than that of ␣ 1 F64C. Again, this is consistent with the structure of the AChBP where the aligned position is at the periphery of the binding site on a region of the ␤ 2 strand that is twisting away and below the binding site.
We measured rates of reaction of differently charged MTS reagents to identify charge-specific regions of the binding pocket (Table I) . Positively charged MTSET reacts significantly faster than negatively charged MTSES at ␣ 1 F64C and ␣ 1 R66C (Fig. 2B) . We conclude that the difference in rates is due to a negative electrostatic potential located within the binding pocket. Based on the AChBP structure, residues in the binding pocket that could potentially form this negative subsite include ␣ 1 E182, ␣ 1 D183 in the loop F region of the GABA-binding site. Negatively charged residues in the homologous region of the muscle nicotinic acetylcholine receptor (␥D174/␦D180) have been identified that are important for acetylcholine binding (36, 37) . Alternatively, the negative subsite could be formed by electrons of aromatic amino acid side chains (38) . Several aromatic residues have been identified that are important for GABA binding (␤ 2 Y97 (39), ␤ 2 Y157, ␤ 2 Y205, (17) ). Experiments are in progress to test these hypotheses.
We speculate that the amino group of GABA is oriented away from ␣ 1 F64 and ␣ 1 R66 and faces toward this negative subsite, whereas the carboxylate group of GABA may be stabilized, at least in part, by ␣ 1 R66. Consistent with this hypothesis, removal of the bidentate positive charge at ␣ 1 R66 increases GABA EC 50 values several hundred-fold. In addition, muscimol, a high affinity agonist of the GABA A receptor, has been shown to photoaffinity label the receptor at ␣ 1 F64 (12) , and the photochemistry of this reaction indicates that the carboxylatelike part of the muscimol molecule reacts with ␣ 1 F64 (40) .
In order to elucidate differences between agonist and antagonist binding, we measured rates of covalent modification in the presence and absence of GABA and SR-95531. Covalent modification of ␣ 1 D62C is slowed by SR-95531 but not GABA, whereas modification of ␣ 1 S68C is slowed by GABA but not SR-95531. In addition, cysteine mutagenesis of ␣ 1 R66 causes a change in GABA EC 50 values but not SR-95531 K I values, whereas mutagenesis of ␣ 1 F64 causes a change in both GABA EC 50 and SR-95531 K I values. Based on these data, we conclude that different amino acid residues within the loop D region of the binding pocket are important for mediating the effects of GABA and SR-95531. This is most likely due to differences in ligand structure and/or ligand positioning within the site.
Most GABA A receptor agonists and antagonists contain a positively and a negatively charged functional group ϳ5 Å apart (41) , similar to the GABA molecule. It is possible that these different classes of compounds bind with their intercharge portion in the same orientation. We have provided evidence that the carboxylate group of GABA likely binds near ␣ 1 F64 and ␣ 1 R66. Thus, like GABA and muscimol, we predict that the negatively charged region of SR-95531 is oriented near ␣ 1 R66 and ␣ 1 F64.
One problem with this prediction is that mutation of ␣ 1 R66 dramatically alters GABA binding but does not affect SR-95531 binding. The larger size of SR-95531 indicates that this molecule likely utilizes more attachment points than GABA within the binding pocket. It is likely that the ring structures of SR-95531 (Fig. 4) provide these additional attachment points. Because the rate of covalent modification of ␣ 1 D62C is slowed in the presence of SR-95531 and is not affected by GABA, we hypothesize that the bulky aromatic rings of SR-95531 are located near ␣ 1 D62. In lieu of a crystal structure of receptor bound with ligand, it is difficult to identify definitively which residues directly contact a ligand.
We demonstrate that conformational movements occur within the binding pocket during channel gating. Pentobarbital increases the rate of covalent modification of ␣ 1 D62C and ␣ 1 S68C suggesting that the conformational change induced by pentobarbital channel gating causes ␣ 1 D62C and ␣ 1 S68C to become more accessible. This may be due to the direct movement of ␣ 1 D62C and ␣ 1 S68C or due to movement of nearby regions of the protein.
The data presented in this study suggest that although the ␣ 1 D62-␣ 1 S68 region is clearly involved in forming the ligandbinding site, the specific interactions of GABA and SR-95531 and the local structural movements associated with these interactions are mediated by different amino acid residues. When GABA binds to the binding site, a conformational change occurs that results in channel activation, whereas when an antagonist binds channel gating is prevented. We speculate that the binding of GABA causes a closure or tightening of the binding pocket that leads to the opening of the channel (18, 42) , and we hypothesize that the binding of an antagonist like SR-95531, which is larger than GABA, prevents complete closure of the pocket, and thus does not allow for channel gating. Further studies identifying specific residues involved in agonist and antagonist recognition within other parts of the binding pocket will lead to a better understanding of the mechanisms behind ligand agonism and antagonism and the process of channel gating.
